A clinical-stage biotechnological company developing immunology-focused treatments out of Singapore was facing challenges maintaining a healthy operational cash flow, and COVID-19 aggravated this as they had to grapple with higher uncertainty of their clinical trial outcomes.
Learn how Marsh helped them overcome the challenge using our extensive industry knowledge and networks, resulting in them providing positive feedback:
“Marsh has been a key partner in the establishment of our D&O and clinical trial insurance policies. They have provided crucial advice to ensure that all aspects of our risk mitigation are covered and we are insured appropriately, considering our US public market listing. Knowing that we have these aspects of our business covered, it allows us to focus more effectively on advancing our clinical trial programs.”